Results 191 to 200 of about 274,125 (232)

Ospemifene for the Treatment of Vulvovaginal Atrophy and Dyspareunia in Postmenopausal Women

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
Vulvovaginal atrophy (VVA) and dyspareunia are common problems experienced by postmenopausal women, although few seek treatment. Symptom‐based therapies include nonhormonal vaginal lubricants, vaginal moisturizers, low‐dose vaginal estrogen, and systemic estrogen.
Amber N, McLendon, Valerie B, Clinard, C Brock, Woodis   +2 more
openaire   +2 more sources

A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy

Menopause, 2018
Abstract Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support ...
Robin J, Bell, Farwa, Rizvi, Rakabul M, Islam, Susan R, Davis   +3 more
openaire   +2 more sources

Comparison of the effect of noninvasive radiofrequency with vaginal estrogen and vaginal moisturizer in the treatment of vulvovaginal atrophy in postmenopausal women: a randomized clinical trial

Menopause
The effect of non-invasive radiofrequency on the treatment of vulvovaginal symptoms of genitourinary syndrome of menopause was similar to vaginal estrogen, except for hormonal cytology, and superior to vaginal moisturizer, with improvement in some ...
Anna Valéria Gueldini de Moraes, L. Costa-Paiva, Helymar da Costa Machado, Tayná Figueiredo Maciel, F. Mariano, A. O. Pedro   +5 more
semanticscholar   +1 more source

Laser Treatment for Vulvovaginal Atrophy

2019
Laser therapy has a therapeutic role for different medical conditions and most recently has gained interest as a non-hormonal treatment for vulvovaginal atrophy or genitourinary syndrome of menopause (GSM). Both microablative fractional CO2 laser and the second-generation non-ablative vaginal Er:YAG laser (VEL) can alleviate the symptoms of dryness and
openaire   +1 more source

Efficacy and safety of a device that combines multipolar radiofrequency with pulsed electromagnetic field for the treatment of vulvovaginal atrophy: a randomized, sham-controlled trial.

Journal of Sexual Medicine
BACKGROUND Vulvovaginal atrophy (VVA) negatively affects the sexual well-being and quality of life of postmenopausal women, yet it is underreported and undertreated.
R. Nappi, Silvia Martella, L. Tiranini, L. Cucinella, Santiago Palacios   +4 more
semanticscholar   +1 more source

[Sulphurous vaginal douching and vulvovaginal atrophy].

La Clinica terapeutica, 2018
During climacteric the reduction or interruption of estrogenic stimulus determines a gradual atrophy of the tissues of the urogenital tract.Vulvovaginal atrophy can be cause of dryness, itch, burning, and dyspareunia. Vulvovaginal atrophy is associated also with depression.
M, Costantino, V, Conti, M B, Marongiu, G, Napolano, A, Filippelli   +4 more
openaire   +1 more source

Abstract PO4-27-04: GRACE-trial: A randomized active-controlled trial for vulvovaginal atrophy in breast cancer patients on endocrine therapy

Cancer Research
Background: Breast cancer is the most common cancer type in women worldwide. Due to hormone receptor positivity in the majority of the breast cancer tumors is endocrine therapy a crucial part in the treatment landscape of breast cancer.
Glenn Vergauwen, Piet Cools, H. Denys, Tom Fiers, K. V. D. Vijver, L. Veldeman, H. Verstraelen   +6 more
semanticscholar   +1 more source

Fractional CO2 Laser for Vulvovaginal Atrophy.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2018
To evaluate the short term efficacy and safety of Fractional CO2 laser for the treatment of vulvovaginal atrophy.From March 2015 to October 2015, 112 menopausal women were recruited. All women with VVA were treated by using Fractional CO2 laser; power 30 watts, 1-3 stacks with 360° vaginal probe for 3 consecutive times, 4 weeks apart.
Orawan, Lekskulchai, Karicha, Mairaing, Nipattha, Vinayanuvattikhun   +2 more
openaire   +1 more source

Treatment of Vulvovaginal Atrophy

JAMA, 2019
openaire   +2 more sources

Quality of life and Satisfaction With Ospemifene for Treating Vulvovaginal Atrophy in Breast Cancer Survivors: Six-Month Results From the PatiEnt SatisfactiON StudY (PEONY).

Clinical Breast Cancer
Paola Villa, C. Cassani, Rossella E. Nappi, V. Bounous, Dorella Franchi, Maurizio Guida, I. Amar, L. Cova, Alessandra Di Lelio, Giusi Graziano, Valentina Trionfera, M. C. Meriggiola   +11 more
semanticscholar   +1 more source